Agendia Establishes Contract with Humana To Cover MammaPrint - Gilde Healthcare

Agendia Establishes Contract with Humana To Cover MammaPrint

October 19, 2010

IRVINE, CA, and AMSTERDAM, THE NETHERLANDS – Agendia, a world leader in molecular cancer diagnostics, announced today that it has established a contract with leading insurance provider Humana to reimburse for the company’s MammaPrint test.  Agendia’s contract with Humana expands the coverage for MammaPrint by more than 17 million lives.  In November 2009, Palmetto GBA, California’s Part B Medicare administrator, established coding guidelines for MammaPrint, allowing healthcare providers from across the United States to submit claims for the test.  MammaPrint is the first and only FDA-cleared breast cancer recurrence test available and has been reimbursed by payors since 2008.

“Humana is dedicated to advancing excellence in healthcare delivery on behalf of its members.  This commitment to quality care and patient safety has now led Humana to include MammaPrint in its medical benefit management program,”

said Bernhard Sixt, Chief Executive Officer of Agendia.

“We are proud that Humana is offering its members coverage for the only gene expression test for breast cancer recurrence which has been cleared by the FDA.”

Humana, headquartered in Louisville, Kentucky, is one of the nation’s largest publicly traded health and supplemental benefits companies, with approximately 10.4 million medical members and approximately 7.2 million specialty-benefit members.  Humana is a full-service benefits-solutions company, offering a wide array of health and supplementary benefit plans for employer groups, government programs and individuals.

About MammaPrint®

MammaPrint is the first and only breast cancer recurrence test cleared by the U.S. Food and Drug Administration (FDA). FDA clearance requires clinical and analytical validation and reporting systems to ensure patient safety issues are addressed.  Highly accurate, MammaPrint identifies patients with early metastasis risk — patients who are likely to develop metastases within five years following surgery.  Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk.  In planning treatment, the MammaPrint test results provide doctors with a clear rationale to assess the benefit of chemotherapy in addition to other clinical information and pathology tests.  All MammaPrint tests are conducted in Agendia’s CAP-accredited and CLIA compliant service laboratories.

About Agendia

Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting-edge genomics platform for tumor gene expression profiling, the company’s tests help physicians more accurately tailor cancer treatments.  Agendia markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. Agendia is based in Irvine, California, and in Amsterdam, the Netherlands.

Media contacts:

Hans Herklots
Agendia
+31.20.462.1557 Office
+31.620.083.509 Mobile
hans.herklots@agendia.com

Todd Aydelotte
Ricochet Public Relations
+1.212.679.3300 x111 Office
todd@ricochetpr.com

Gilde Healthcare company Volta Medical announces positive results from transatlantic trial on AI-assisted ablation for persistent atrial fibrillation

TAILORED-AF randomized controlled trial (RCT) findings demonstrated superiority in freedom from atrial fibrillation (AF) at 12 months from a tailored cardiac ablation guided by artificial intelligence (AI) when compared to pulmonary vein isolation (PVI) alone....
May 21, 2024

Gilde Healthcare co-leads $100M equity financing in Karius

Karius®, Inc., a world leader in genomic diagnostics for infectious disease, today announced it has secured $100 million in Series C funding. The round was co-led by Gilde Healthcare, Khosla Ventures and 5AM Ventures, and...
May 2, 2024

Gilde Healthcare company Ablative Solutions demonstrates Significant Reduction in Blood Pressure meeting its primary endpoint in Pivotal Trial

Ablative Solutions, Inc., announced that primary trial results from the TARGET BPI Pivotal Trial, evaluating alcohol-mediated renal denervation with the Peregrine SystemTM Kit, were presented as a Late-Breaking Clinical Trial at the American College of...
April 11, 2024